In an initial decision on November 16, 2016, Chinese State Intellectual Property Office Patent Reexamination Board invalidated Novartis’ Chinese Patent No. 01809781.2 related to treatment of advanced malignancies involving bone and tumor-induced hypercalcaemia and the drug Zometa (zoledronic acid) for lack of novelty and inventiveness. Please note that this decision can be subject to judicial review. Keep posted.